Wednesday, February 10, 2010, 6:17pm SGT - The Singapore stock market is closed.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Affymax, Inc. (AFFY)

At 5:00AM SGT: 20.26 USD   0.00 (0.00%)  
 MORE ON AFFY 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Affymax, Inc. (NGM:AFFY) Delayed quote dataEdit
Last Trade:20.26 USD
Trade Time:5:00AM SGT
Change: 0.00 (0.00%)
Prev Close:20.26
Open:N/A
Bid:N/A
Ask:N/A
1y Target Est:31.83
Day's Range:N/A - N/A
52wk Range:11.79 - 25.64
Volume:0
Avg Vol (3m):153,427
Market Cap:387.41M
P/E (ttm):N/A
EPS (ttm):-5.05
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y 
Use Y! Toolbar to track stocks
 Add AFFY to Portfolio   Download Data

 HEADLINES 
•10 Biotech Stocks on Clinical Trials Watch
at TheStreet.com (Thu, Feb 4)
•Affymax to Present at the 12th Annual BIO CEO & Investor Conference
Business Wire (Mon, Feb 1)
•Amgen Up Despite Q4 Sales, Profit Miss
at Barrons.com (Tue, Jan 26)
•Affymax Completes Treatment and Last Patient Follow-up in Phase 3 Program for Investigational Drug, Hematide, to Treat Anemia in Chronic Renal Failure
Business Wire (Mon, Jan 25)
•AFFYMAX INC Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Tue, Jan 12)
•Amgen's Anemia Drug Risks; Vivus Aids Sleep Apnea: BioBuzz
at TheStreet.com (Thu, Jan 7)
•FDA to Review Amgen Drugs: BioBuzz
at TheStreet.com (Thu, Jan 7)
•Affymax to Present at the 28th Annual JP Morgan Healthcare Conference
Business Wire (Tue, Jan 5)
•AFFYMAX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
EDGAR Online (Fri, Dec 11)
•Affymax to Present at Piper Jaffray 21st Annual Healthcare Conference
Business Wire (Tue, Dec 1)
•Research Firm Lays Out Surprise Bio Events for 2010: BioBuzz
at TheStreet.com (Tue, Dec 1)
More Headlines for AFFY...
 ANALYST 
EPS Est (next year) (Dec-09) :-4.72
EPS Est (in 2 years) (Dec-10) :-1.10
Avg Rec (current)*:1.5
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Affymax, Inc., a biopharmaceutical company, engages in the development of peptide-based drug candidates to enhance the treatment of serious and life-threatening conditions.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices